Prestige-Cytiva partnership and new Korean R & D facility

Home/Pharma News | Posted 09/07/2021 post-comment0 Post your comment

Singapore-based Prestige BioPharma, which specializes in the development of antibody therapeutics, is to build a new research and development (R & D) facility in the Republic of Korea and has entered a strategic partnership with Cytiva.

134 AA010709

In addition, the company has recently expanded into vaccine development and production and participated in the production of Russia's Sputnik V COVID-19 vaccine.

R & D facility in Korea
The new US$152 million Prestige R & D facility, measuring 45,000 square meters, will be in Busan City. In the next five years, it is to initially employ 209 highly qualified professionals. Through a memorandum of understanding with Busan City, Prestige will cooperate in creating a bio-cluster that supports a local economy and drives mutual growth in academia and industry.

Prestige’s Herceptin® (trastuzumab) biosimilar has successfully completed its phase III clinical trial and is currently under European Medicines Agency (EMA) review. The company’s pipeline also includes its proprietary first-in-class antibody for treating pancreatic cancer. This has been designated as an Orphan Drug by US Food and Drug Administration (FDA), European Medicines Agency (EMA) and Korean Ministry of Food and Drug Safety (MFDS).

Cytiva partnership
On 27 April 2021, Prestige announced its strategic partnership with Cytiva. Through this partnership, Cytiva will supply equipment for cell culture and purification that will be used for biologicals and vaccine production. Cytiva will also provide technologies and solutions for bio-manufacturing to facilitate rapid production of multiple products.
In turn, Prestige will procure bioprocessing equipment including that required to produce Russia's Sputnik V COVID-19 vaccine.

This partnership will facilitate Prestige’s vaccine centre’s test operation, which is expected to begin in August 2021, aiming to start full production of 100 million doses of vaccine per month from September 2021.

Related articles
Bevacizumab and insulin aspart non-originator biologicals to be sold in Russia

Korean biosimilars makers pipelines and expansion


The brand-new section the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. 

View this week’s headline article: Biosimilares en Japón: una perspectiva general

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Biosimilares en Japón: una perspectiva general

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010